Skip to main content

Urea Cycle Disorders, Inborn

2
Pipeline Programs
2
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Human BioSciences
Human BioSciencesWV - Martinsburg
1 program
1
N-carbamylglutamatePhase 21 trial
Active Trials
NCT01341379Withdrawn0Est. Aug 2012
Korro Bio
Korro BioMA - Cambridge
1 program
1
KRRO-121Phase 1/2

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Human BioSciencesN-carbamylglutamate

Clinical Trials (1)

NCT01341379Human BioSciencesN-carbamylglutamate

Increasing Ureagenesis in Inborn Errors of Metabolism With N-Carbamylglutamate

Start: Dec 2010Est. completion: Aug 20120
Phase 2Withdrawn

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.